JP Morgan Maintains Overweight on Elevance Health, Raises Price Target to $631
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains an Overweight rating on Elevance Health (NYSE:ELV) and raises the price target from $628 to $631.
May 30, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Lisa Gill maintains an Overweight rating on Elevance Health and raises the price target from $628 to $631.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to positively influence investor sentiment and drive short-term price appreciation for Elevance Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100